The inspection was conducted from 23rd June 2025 to 25th June 2025, concluded with zero Form-483 observations.

The company said that the 'Central Laboratory Analytical Services' is its independent testing laboratory, and this was the second successful USFDA inspection for the facility.

SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specializing in APIs and intermediates for global customers. The company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag.

The company's consolidated net profit jumped 17.6% to Rs 20.32 crore on 1% increase in net sales to Rs 248.20 crore in Q4 FY25 over Q4 FY24.

The counter added 2.31% to end at Rs 239.05 on the BSE.

Powered by Capital Market - Live News